Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilematovir - Janssen Sciences Ireland UC

Next Previous
Search
Drug Profile

Rilematovir - Janssen Sciences Ireland UC

Alternative Names: JNJ-53718678; JNJ-678; JNJ-8678

Latest Information Update: 07 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Developer Janssen Research & Development; Janssen Sciences Ireland UC
  • Class Antivirals; Halogenated hydrocarbons; Imidazoles; Indoles; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 07 Jan 2025 No development reported - Phase-III for Respiratory syncytial virus infections (In neonates, In infants, In children) in Poland, Spain, Germany, Sweden, Czech Republic, Hungary, Belgium, Poland, USA (PO)
  • 23 May 2022 Janssen Sciences Ireland completes pre-approval access programme for Respiratory Syncytial Virus (In Adults, In Children, In the elderly) in Hungary, Italy, Spain, Sweden, and the United Kingdom (PO) in May 2022 (NCT04221412)
  • 28 Apr 2022 Janssen Research and Development terminates a phase IIb PRIMROSE trial in Respiratory syncytial virus infections (In adults, In the elderly) in Argentina, Bulgaria, Canada, Germany, Hungary, Italy, Japan,Poland, South Africa, Spain, Sweden, Thailand, Ukraine and in the US, due strategic decision (NCT04978337).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top